Free Webinar | Harnessing the power of the BioXp™ system to combat COVID-19
September 21, 2021 | 11:00 am – 12:00 pm EDT
What Does It Cover?
The COVID-19 pandemic has caused global social and economic devastation. At the onset of the pandemic, accelerating the pace of innovation was paramount as the scientific community raced to advance solutions for the prevention, detection, and treatment of the disease. Throughout the pandemic, synthetic biology has helped enable the rapid development of diagnostic assays, prophylactic vaccines, and therapeutic antibodies through DNA writing technologies.
In this webinar course we will describe Codex DNA’s production of a complete synthetic genome of SARS-CoV-2 by utilizing its automated DNA synthesis platform, the BioXp™ system. The BioXp™ system is the world’s only fully automated benchtop instrument that enables numerous synthetic biology workflows by providing a turn-key, end-to-end solution for generating synthetic DNA and mRNA starting from digital DNA sequences.
The BioXp™ System was used to generate de novo fragments spanning the entire SARS-CoV-2 genome in a single, overnight run. Following the synthesis, the fragments were combined using a 3-stage hierarchical assembly using the Gibson Assembly® method. Since the generation of the first synthetic genome of SARS-CoV-2, Codex DNA has created nearly 40 different SARS-CoV-2 genomes for several variants and sub-genomic replicons that have been widely used by researchers around the world as diagnostic controls and for vaccine and therapeutic discovery.
Codex DNA’s solutions for designing and building genomes with the BioXp™ system are a disruptive technology that accelerates the scientific process. With the ability to synthesize highly accurate dsDNA molecules and enable rapid iteration cycles of design and synthesis, the BioXp™ system can extend the discovery capabilities of researchers against other infectious agents beyond SARS-CoV-2.
What Will You Learn?
Who Should Attend?
Krishna Kannan, PhD
Director of R&D at Codex DNA